⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ONCO News
Onconetix, Inc. Common Stock
Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company
globenewswire.com
ONCO
OncoHost Wins 2026 BIG Innovation Award in Health Category; Named a Top 10 Innovator - Small Business
prnewswire.com
ONCO
O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
globenewswire.com
ONCO
Provident Healthcare Partners Advises Chesapeake Oncology-Hematology Associates on its Partnership with Chesapeake Urology Associates
prnewswire.com
ONCO
Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight
prnewswire.com
BNTX
NVCR
ONCO
AZN
MRK
MRUS
OncoHost Named Gold Winner in 2025 Merit Awards for Healthcare - Technology Solution of the Year
prnewswire.com
ONCO
Onco3R Therapeutics Announces Completion of First Multiple Ascending Dose Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671
globenewswire.com
ONCO
OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting USA - English USA - Français USA - Deutsch USA - español USA - English
prnewswire.com
ONCO
Lors de la 67e réunion annuelle de l'ASH, OncoPrecision a annoncé la présentation orale de ONC001, un conjugué anticorps-médicament ciblant le récepteur CD64, premier de sa catégorie, pour la leucémie monocytaire. USA - Français USA - English USA -
prnewswire.com
ONCO
OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting USA - English USA - Deutsch USA - Français USA - español USA - English
prnewswire.com
ONCO